Drugs

RetailWalgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst says
By Sasha RogelbergMarch 29, 2024

FinanceCanopy Growth faced bankruptcy prospects last year. Now its shares are surging as Germany decriminalizes cannabis
By Steve MollmanMarch 22, 2024

RetailWegovy and Ozempic have ignited a gold rush in pharma as well as an upsurge in fake ‘skinny jabs’, leading to surge in hospitalizations
By Ashleigh Furlong and BloombergMarch 13, 2024

HealthMark Cuban’s $141K mistake: The Cost Plus Drugs cofounder says CEOs don’t understand health care coverage, and it’s costing them big
By Lindsey LeakeMarch 8, 2024

By Lindsey LeakeMarch 4, 2024

By Matthew Perrone and The Associated PressMarch 4, 2024

By Andrew DeMillo and The Associated PressMarch 4, 2024

TechFormer YouTube CEO’s son found dead in UC Berkeley dorm, leaving prominent Silicon Valley family ‘devastated beyond comprehension’
By Steve MollmanFebruary 18, 2024

By Arthur Allen and KFF Health NewsFebruary 16, 2024

By Richard EisenbergFebruary 9, 2024

By Virginia Van Natta and BloombergFebruary 4, 2024

HealthNorth Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
Most Popular





